To evaluate the safety and clinical efficacy of combining the TGF-β1 receptor type I inhibitor galunisertib with sorafenib in patients with advanced hepatocellular carcinoma.
Conducted a Phase 2 clinical trial evaluating combination therapy in patients diagnosed with advanced hepatocellular carcinoma.
Administered galunisertib in combination with sorafenib to assess safety profiles and survival outcomes.
The combination regimen demonstrated an acceptable safety profile in patients with advanced hepatocellular carcinoma.
Treatment with galunisertib plus sorafenib resulted in prolonged overall survival outcomes without specific numerical values reported.
Abstract
The combination of galunisertib and sorafenib showed acceptable safety and a prolonged OS outcome.